Table 1.
Patient characteristics
| Total | Treatment | |||
|---|---|---|---|---|
| RA patients n = 370 | No anti-TNF n = 370 | Anti-TNF n = 120 |
p | |
| Mean age (sd) | 59.1 (13.7) | 60.8 (13.9) | 55.7 (12.8) | 0.001 |
| Female gender (%) | 272 (73.5) | 177 (71) | 95 (79) | 0.10 |
| Median nr years with RA (min-max) | 8.5 (0-54) | 8.7 (0-54) | 8.3 (0-46) | 0.13 (MW) |
| Anti-CCP positive (%)a | 104/125 (83.2) | 75/90 (83) | 29/35 (83) | 1.0 |
| Reumatoid factor positive (%) | 337/369 (91.3) | 228 (91) | 109/119 (92) | 1.0 |
| Erosion (%) | 291/357 (81.5) | 189/243 (78) | 102/114 (90) | 0.008 |
| Geometric mean number of DMARDs (95% CI) | 2.96 (2.79-3.13) | 2.37 (2.22-2.52) | 4.69 (4.41-4.99) | < 0.001 |
| Geometric mean DMARDs per disease year (95% CI) | 0.42 (0.37-0.47) | 0.37 (0.31-0.43) | 0.55 (0.47-0.64) | 0.001 |
| Number of patients with current or past use of DMARDs (%) | ||||
| Methotrexate | 331 (89.5) | 212 (85) | 119 (99) | < 0.001 |
| Salazopyrine | 262 (70.8) | 162 (65) | 100 (83) | < 0.001 |
| Antimalaria | 176 (47.6) | 105 (42) | 71 (59) | 0.003 |
| Leflunomide | 33 (8.9) | 16 (6) | 17 (14) | 0.02 |
| Intramuscular gold | 55 (14.9) | 36 (14) | 19 (16) | 0.76 |
| Infliximab | 35 (9.5) | 0 | 35 (29) | < 0.001 |
| Etanercept | 61 (16.5) | 0 | 61 (51) | < 0.001 |
| Adalilumab | 60 (16.2) | 0 | 60 (50) | < 0.001 |
| Anakinra | 14 (3.8) | 2 (1) | 12 (10) | < 0.001 |
| Oral corticosteroids | 164 (44.3) | 103 (41) | 61 (51) | 0.09 |
| Azathioprine | 33 (8.9) | 13 (5) | 20 (17) | 0.001 |
| Others | ||||
| n = 1 | 32 (8.6) | 17 (6.8) | 15 (12.5) | 0.01 |
| n = 2 | 5 (1.4) | 1 (0.4) | 4 (3.3) | |
a Anti-CCP was not routinely analyzed.
MW: Mann Witney